Disclaimer: The following information is intended for medical professionals and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Clinical presentations vary, and management should be individualized based on institutional protocols, specialist consultation, and current clinical guidelines.

---

Retinoblastoma

Overview

Definition

Retinoblastoma is the most common primary intraocular malignancy in children. It originates from the primitive neuroectodermal cells (retinoblasts) of the retina. The tumor may be unifocal or multifocal, unilateral (one eye) or bilateral (both eyes).

Epidemiology

• Incidence: Approximately 1 in 15,000 to 20,000 live births globally.
• Age of Onset:
• 95% of cases are diagnosed before age 5.
• Average age of diagnosis: 12 months for bilateral cases; 24 months for unilateral cases.
• Demographics: No clear gender or racial predilection.
• Global Burden: Higher mortality rates are observed in low-to-middle-income countries due to delayed diagnosis.

Classification

1. Heritable (Germline) Retinoblastoma (40%):
   • Constitutional mutation in the RB1 gene.
   • Usually bilateral (can be unilateral) and multifocal.
   • Transmissible to offspring (autosomal dominant with high penetrance).
   • Risk of trilateral retinoblastoma (associated pinealoblastoma) and secondary non-ocular malignancies.
2. Non-heritable (Somatic) Retinoblastoma (60%):
   • Acquired mutations in the RB1 gene exclusively within the retinal cell.
   • Always unilateral and unifocal.
   • Not transmissible; no increased risk of second primary malignancies.

---

Pathophysiology

Mechanism

• Tumor Suppressor Gene: The disease is caused by the inactivation of the RB1 tumor suppressor gene located on chromosome 13q14.
• Knudson’s "Two-Hit" Hypothesis:
  • Heritable: The "first hit" (mutation) is inherited in all cells of the body. The "second hit" occurs spontaneously in a retinal cell.
  • Non-heritable: Both "hits" occur spontaneously within a single somatic retinal cell.
• Cellular Effect: Loss of RB1 function leads to unregulated cell cycle progression at the G1/S checkpoint due to the absence of the pRb protein, resulting in uncontrolled proliferation.

Risk Factors

• Parental History: Positive family history of retinoblastoma (strongest risk factor for heritable type).
• Advanced Parental Age: Associated with new germline mutations (specifically paternal age).

---

Clinical Presentation

Signs and Symptoms

Cardinal Features

• Leukocoria (White Pupillary Reflex): The most common presenting sign (60% of cases). Often described by parents as a "cat's eye reflex" or noticed in flash photography.
• Strabismus: The second most common sign (20%). Usually exotropia or esotropia resulting from loss of central vision.

Early Signs

• Changes in iris color (heterochromia iridis) due to neovascularization.
• Poor visual tracking or fixation in an infant.

Advanced Signs

• Red, painful eye: Secondary to glaucoma or inflammation.
• Proptosis: Suggests extraocular orbital extension.
• Orbital Cellulitis-like presentation: Sterile orbital inflammation from tumor necrosis.
• Hyphema: Blood in the anterior chamber (rare).

Physical Examination

• Red Reflex Testing (Bruckner Test): Critical screening tool. Asymmetry, dark spots, or white reflexes require immediate referral.
• External Exam: Evaluate for strabismus, proptosis, or pseudohypopyon.

---

Diagnostic Approach

History Taking

• Key Questions:
  • When was the white reflex or eye turn first noticed?
  • Is there a family history of eye tumors, enucleation, or childhood blindness?
  • Did the child have a premature birth (exclude Retinopathy of Prematurity)?
  • Any history of ocular trauma (exclude hyphema/cataract)?

Imaging

Recommended

• B-Scan Ultrasonography:
  • High sensitivity for detecting intraocular calcification (hallmark of retinoblastoma).
  • Assesses tumor dimensions.
• MRI of Brain and Orbits:
  • Gold standard for evaluating the optic nerve and extraocular extension.
  • Used to screen for midline intracranial tumors (Trilateral Retinoblastoma).
  • Protocol: Thin-section orbital sequences with and without contrast.

Advanced/Contraindicated

• CT Scan: Generally avoided in pediatric patients to minimize ionizing radiation exposure, which increases the risk of secondary malignancies in RB1 mutation carriers.
• Optical Coherence Tomography (OCT): Hand-held OCT is used in specialized centers to evaluate macular involvement in very small tumors.

Systemic Workup

• Genetic Testing: Essential for all patients. Peripheral blood analysis for RB1 mutation.
• Bone Marrow Aspiration/Lumbar Puncture: Only indicated if there is clinical or radiographic evidence of extraocular spread.

Diagnostic Biopsy

• WARNING: Intraocular biopsy is typically CONTRAINDICATED due to the high risk of tumor seeding into the extraocular space. Diagnosis is clinical and radiographic.

---

Management

Treatment Goals

1. Save the patient's life.
2. Salvage the eye (globe preservation).
3. Preserve maximize vision.

Staging (International Intraocular Retinoblastoma Classification - IIRC)

Current management is driven by the IIRC grouping (A through E):

• Group A: Small tumors (<3mm), away from foveola/disk.
• Group B: Larger tumors (>3mm), macular/juxtapapillary location, or subretinal fluid <3mm from tumor.
• Group C: Focal subretinal seeds or extensive subretinal fluid.
• Group D: Diffuse subretinal or vitreous seeding.
• Group E: Extensive tumor (>50% of globe), neovascular glaucoma, hyphema, or signs indicating the eye cannot be saved or vision is lost.

Treatment Algorithms

1. Enucleation (Surgical Removal)

• Indications: Unilateral Group E tumors; cases where the eye is blind/painful; suspected optic nerve invasion; inability to follow up.
• Procedure: Removal of the globe with a long section of the optic nerve to ensure clear margins.

2. Focal Therapies (Conserve the Eye)

• Indications: Group A tumors or residual tumors after chemotherapy.
• Cryotherapy: For anterior small tumors.
• Laser Photocoagulation/Thermotherapy: For posterior small tumors.

3. Chemotherapy Options

Used for chemoreduction to shrink tumors (Groups B, C, D) allowing for focal consolidation.

• Intravenous Chemotherapy (IVC):
  • Standard Regimen: VEC (Vincristine, Etoposide, Carboplatin).
  • Standard for bilateral disease or younger infants.
• Intra-arterial Chemotherapy (IAC):
  • Direct catheterization of the ophthalmic artery.
  • Agents: Melphalan, Topotecan, Carboplatin.
  • High globe salvage rate for Group C/D; minimizes systemic side effects.
• Intravitreal Chemotherapy:
  • Direct injection into the vitreous body.
  • Indication: Recurrent or resistant vitreous seeding.
  • Agents: Melphalan or Topotecan.
  • Note: Safety enhanced by cryotherapy at the injection site to prevent reflux.

4. Radiotherapy

• External Beam Radiotherapy (EBRT): Historically used but now largely abandoned as first-line due to severe orbital deformity and high risk of secondary malignancies in germline patients. Used now only for salvage.
• Plaque Brachytherapy: Radioactive plaque (Iodine-125) sutured to sclera for focal solitary tumors.

---

Complications

Common (Treatment-Related)

• Chemotherapy: Neutropenia, infection, ototoxicity (carboplatin), nephrotoxicity.
• IAC specific: Eyelid edema, ptosis, choroidal ischemia, vascular occlusion.

Serious

• Metastasis: Spread to CNS (via optic nerve), bone marrow, or liver.
• Trilateral Retinoblastoma: Intracranial neuroblastic tumor (usually pineal region); extremely poor prognosis.

Long-term

• Secondary Primary Malignancies (SPMs): Cumulative risk in germline patients is ~1% per year.
  • Common types: Osteosarcoma, soft tissue sarcomas, cutaneous melanoma.
  • Risk is significantly increased by external beam radiation.

---

Prognosis

• Survival:
  • High-income countries: >95% 5-year survival.
  • Low-income countries: <50% due to late presentation/extraocular spread.
• Visual Outcome: Depends heavily on tumor location. Tumors involving the fovea likely result in permanent central vision loss, though peripheral vision may be maintained.
• Globe Salvage:
  • Group A/B: >90% success.
  • Group D: 50-70% success with IAC.

---

Special Populations

Pediatric Considerations

• Follow-up: Examinations Under Anesthesia (EUA) are required frequently (every 3-4 weeks during active treatment, spacing out over years) until retinal maturation (approx age 5-7).
• Anesthesia Risk: Repeated anesthesia in young children has raised concerns regarding neurodevelopment; however, visual salvage usually necessitates this risk.

Genetic Carriers (Family Members)

• Siblings of a patient with retinoblastoma must undergo screening EUAs until RB1 status is confirmed.
• If the patient has a germline mutation, parents and siblings require genetic counseling.

---

Clinical Pearls

• Diagnostic Pearl: A white pupillary reflex in a photo is not diagnostic but warrants referral. Always differentiate from Coats disease (exudative retinopathy, usually unilateral, older boys) and PFV (Persistent Fetal Vasculature).
• Therapeutic Pearl: "Chemoreduction" is not curative alone; it shrinks the tumor to make it amenable to focal laser or cryotherapy.
• Pitfall: Never perform a vitrectomy or anterior chamber paracentesis in a child with an undiagnosed intraocular mass; this can convert an intraocular tumor into an extraocular malignancy.

---

Recent Updates

• Liquid Biopsy: Research suggests aqueous humor aspiration (which is safer than vitreous biopsy when controlled) may yield tumor DNA (ctDNA) for genetic profiling and prognosis without enucleation.
• Moving away from Systemic Chemo: There is a strong paradigm shift toward Intra-arterial Chemotherapy (IAC) as first-line for unilateral Group D disease to spare children systemic toxicity.
• Intravitreal Safety: Previous dogma prohibited intravitreal injections. Current evidence shows standard safety protocols (using cryo-needle withdrawal techniques) make intravitreal melphalan safe and effective for seeding.

---

Key References

1. Guidelines: National Comprehensive Cancer Network (NCCN) Guidelines for Retinoblastoma.
2. Classification System: Murphree AL. intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005.
3. Landmark Study: Abramson DH, et al. Ophthalmic Artery Chemosurgery for Retinoblastoma: Five Year Outcome. Ophthalmology. 2015.
4. Review: Dimaras H, et al. Retinoblastoma. Nat Rev Dis Primers. 2015.